BD和Babson Diagnostics向医疗机构推出创新的指尖血液检测-动脉网

BD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations

碧迪医疗等信源发布 2024-12-17 19:56



可切换为仅中文







FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S.

新泽西州富兰克林湖和德克萨斯州奥斯汀，2024年12月17日/PRNewswire/-BD（Becton，Dickinson and Company）（纽约证券交易所：BDX），一家领先的全球医疗技术公司，以及一家科学第一的医疗保健技术公司Babson Diagnostics，今天宣布扩展指尖血液采集和测试技术，供美国使用。

health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings..

卫生系统和其他大型提供者网络，如紧急护理、医生办公室和其他门诊护理环境。。

This innovative blood testing process integrates BD's MiniDraw™ Capillary Blood Collection System with Babson's BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient's finger. With this less-invasive alternative to venipuncture blood draws, samples can be collected and prepared by any trained health care worker — including those without prior phlebotomy experience..

这种创新的血液测试过程将BD的MiniDraw™毛细血管采血系统与Babson的BetterWay技术相结合，可以从患者手指采集的少至六滴毛细血管血液中获得测试结果。使用这种侵入性较小的静脉穿刺抽血替代方法，任何训练有素的医护人员都可以收集和制备样本，包括那些没有静脉切开术经验的医护人员。。

With 70% of clinical decisions informed by diagnostic results, blood tests are a routine part of care to help clinicians diagnose, monitor and treat patients. This novel capillary solution enables care providers to improve access to blood testing in underserved locations that do not have phlebotomy capabilities, while lowering common barriers to testing such as fear of needles and logistical challenges..

70%的临床决策由诊断结果告知，血液检查是帮助临床医生诊断，监测和治疗患者的常规护理部分。这种新颖的毛细血管解决方案使护理人员能够在没有静脉切开能力的服务不足的地点改善血液检测的机会，同时降低常见的检测障碍，例如对针头的恐惧和后勤挑战。。

'In areas of the U.S. where there are gaps in services or shortages of trained phlebotomy professionals, patients may experience delays in blood draws or not receive care they need,' said Bridget Bagnato, worldwide president of Specimen Management at BD. 'By simplifying one of the most common procedures, together we're making blood testing less invasive and more convenient to help health care organizations increase efficiency and access while helping to improving patient satisfaction and outcomes.'.

BD标本管理全球总裁布里奇特·巴格纳托（BridgetBagnato）说：“在美国服务存在差距或缺乏训练有素的静脉切开专业人员的地区，患者可能会出现抽血延迟或无法获得所需的护理。通过简化最常见的程序之一，我们一起使血液检测的侵入性更小，更方便，以帮助医疗保健组织提高效率和获取机会，同时帮助提高患者满意度和结果。”。

The commercial partnership is an expansion of BD and Babson's collaboration to advance capillary blood testing, which started in 2016 and has since evolved into a strategic partnership.

该商业伙伴关系是BD和Babson合作推进毛细血管血液检测的扩展，该合作始于2016年，现已发展为战略伙伴关系。

'BetterWay and BD MiniDraw™ are defining what's next in health care,' said David Stein, Babson's CEO. 'BD has been innovating blood collection technology for 75 years and we believe our partnership will deliver a potentially transformative technology to support innovative and patient-focused health care organizations in better reaching and serving patients.'.

Babson首席执行官大卫·斯坦（DavidStein）说，BetterWay和BD MiniDraw™正在定义医疗保健的下一步BD一直在创新采血技术75年，我们相信我们的合作伙伴关系将提供一种潜在的变革性技术，以支持创新和以患者为中心的医疗保健组织更好地接触和服务患者。”。

BetterWay blood testing has been available in retail settings since May 2024, expanding access to blood collection to new locations, including local pharmacies. This continued expansion will bring it to patients in ambulatory care sites throughout the United States.

自2024年5月以来，BetterWay血液检测已在零售环境中提供，从而将血液采集的渠道扩大到包括当地药店在内的新地点。这种持续的扩张将为美国各地门诊护理场所的患者带来它。

About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers.

关于BDBD是世界上最大的全球医疗技术公司之一，正在通过改进医疗发现、诊断和护理服务来促进世界健康。该公司通过开发创新技术、服务和解决方案来支持医疗保健前线的英雄，这些技术、服务和解决方案有助于推进患者的临床治疗和医疗保健提供者的临床过程。

BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

BD及其70000多名员工充满热情并致力于帮助提高临床医生护理过程的安全性和效率，使实验室科学家能够准确检测疾病，并提高研究人员开发下一代诊断和治疗方法的能力。

BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

BD在几乎每个国家都有业务，并与世界各地的组织合作，以解决一些最具挑战性的全球健康问题。通过与客户密切合作，BD可以帮助提高成果，降低成本，提高效率，提高安全性并扩大医疗保健的范围。

For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. .

有关BD的更多信息，请访问BD.com或通过LinkedIn与我们联系，网址为www.LinkedIn.com/company/bd1/，X（以前的Twitter）@BDandCo或Instagram@becton\u dickinson。。

About Babson DiagnosticsBabson Diagnostics is a science-driven healthcare technology company that has reimagined blood testing with the launch of its BetterWay blood testing service. BetterWay's patient-friendly, fingertip collection process and ability to be administered without phlebotomists improves population health by increasing adherence to testing.

关于Babson Diagnostics Babson Diagnostics是一家科学驱动的医疗保健技术公司，它通过推出BetterWay血液检测服务重新设想了血液检测。BetterWay对患者友好的指尖采集过程以及在没有静脉切开术的情况下进行管理的能力通过增加对测试的依从性来改善人群健康。

BetterWay for Healthcare Organizations enables health systems and other provider organizations to acquire new patients, increase health equity, and reduce the overall cost of care by deploying BetterWay in a broad range of ambulatory care settings, including physician practices, urgent care clinics, and at community events.

BetterWay for Healthcare Organizations通过在广泛的门诊护理环境中部署BetterWay，包括医生实践、紧急护理诊所和社区活动，使卫生系统和其他提供者组织能够获得新患者，增加健康公平性，并降低整体护理成本。

The end-to-end BetterWay solution seamlessly integrates BD's MiniDraw capillary collection system with proprietary Babson technologies, including its patented hand warming and sample preparation devices. For more information, visit betterway.com/healthcare-organizations.

端到端BetterWay解决方案将BD的MiniDraw毛细管收集系统与专有的Babson技术无缝集成，包括其专利的暖手和样品制备设备。有关更多信息，请访问betterway.com/healthcare-organizations。

Forward-Looking StatementsThis press release contains certain forward-looking statements regarding the expansion of the use of BD and Babson's fingertip blood collection and testing technologies. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including, without limitation, competitive factors, including the development of new technologies or products by other companies, changes in healthcare practices, the impact of governmental regulation, future market conditions, manufacturing difficulties or delays, or other factors listed in BD's 2024 Annual Report on Form 10-K and other filings with the SEC.

前瞻性声明本新闻稿包含有关扩大BD和Babson指尖血液采集和测试技术使用的某些前瞻性声明。前瞻性陈述涉及可能导致实际结果与此类陈述中明示或暗示的结果产生重大差异的风险和不确定性，包括但不限于竞争因素，包括其他公司开发新技术或产品、医疗保健实践的变化、政府监管的影响、未来市场状况、制造困难或延误，或BD 2024年年度报告（表10-K）和其他提交给SEC的文件中列出的其他因素。

BD expressly disclaims any undertaking to update any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations..

BD明确拒绝承诺更新本文所述的任何前瞻性声明，以反映本协议日期后的事件或情况，除非适用法律或法规要求。。

Contacts:

联系人：

BD Media Contact:

BD媒体联系人：

BD Investor Contact:

BD投资者联系人：

Troy Kirkpatrick

特洛伊·柯克帕特里克

Adam Reiffe

亚当·瑞夫

VP, Public Relations